A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

March 8, 2019

Study Completion Date

March 8, 2019

Conditions
Obesity
Interventions
DRUG

JNJ-64565111 Dose Level 1

Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.

DRUG

JNJ-64565111 Dose Level 2

Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.

DRUG

JNJ-64565111 Dose Level 3

Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.

DRUG

Liraglutide

Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

DRUG

Placebo

Participants will receive matching placebo SC once-weekly until Week 26.

Trial Locations (51)

2650

UZ Antwerpen, Edegem

3000

UZ Leuven, Leuven

3980

Practimed Medical Center, Tessenderlo

4000

CHU de Liège, Liège

6700

CSL Arlon, Arlon

8800

AZ Delta, Roeselare

9300

OLV Ziekenhuis Aalst, Aalst

9600

AZ Glorieux Ronse, Ronse

10065

Weill Cornell Medicine, New York

13104

Central New York Clinical Research, Manlius

21152

PharmaSite, Malmo

25220

PharmaSite, Helsingborg

29464

Coastal Carolina Research Center, Mt. Pleasant

32277

Care Partners Clinical Research, Jacksonville

40213

L-Marc Research Center, Louisville

41345

Intern Medicin, Gothenburg

42144

PTC,Primary care Trial Center, Gothenburg

44122

Rapid Medical Research, Cleveland

47714

Medisphere Medical Research Center, Llc, Evansville

50630

Katarina Berndtsson-Blom Ladulaaskliniken, Borås

53226

Allegiance Reserach Specialists, LLC, Wauwatosa

75230

Dallas Diabetes Research Center, Dallas

79761

Permian Research Foundation, Odessa

83642

Advanced Clinical Research, Boise

84088

Advanced Clinical Research, West Jordan

85020

Central Phoenix Medical Clinic, Phoenix

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Renton

01752

Milford Emergency Associates, Inc., Marlborough

02886

Omega Medical Research, Warwick

N1R 7L6

Joanne F. Liutkus Medicine Professional Corporation, Cambridge

M3J 2C5

Canadian Phase Onward, Toronto

M9V 4B4

Dr. Anil K Gupta Medicine Professional Corporation, Toronto

M9W 4L6

Manna Research, Toronto

G6W 0M5

Manna Research, Lévis

H9R 4S3

Manna Research, Pointe-Claire

G1V 4W2

Clinique des Maladies Lipidiques de Québec, Québec

15-281

Indywidualna Praktyka Lekarska, Gabinet Leczenia Otyłości i Chorób Dietozależnych, Bialystok

80-546

Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk

40-767

NZOZ 'Linia' Centrum Leczenia Zaburzeń Metabolicznych Magdalena Olszanecka-Glinianowicz, Katowice

40-752

Nzoz Salvia, Katowice-Ligota

60-589

Centrum Zdrowia Metabolicznego Paweł Bogdański, Poznan

701 85

Avdelningen för kliniska prövningar, Örebro

541 50

PTC- Skaraborg, Skövde

BS10 5NB

Southmead Hospital, Bristol

S40 4AA

Ashgate Medical Practice, Chesterfield

SN14 6GT

Hathaway Medical Centre, Chippenham

L9 7AL

Aintree University Hospital NHS Trust, Liverpool

S65 1DA

Clifton Medical Centre, Rotherham

NN8 4RW

Albany House Medical Centre, Wellingborough

BA15 1DQ

Bradford on Avon and Melksham Health Partnership, Wiltshire

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03486392 - A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants | Biotech Hunter | Biotech Hunter